Skip to main content

Table 1 Clinical, demographic and T-cell characteristics of the experimental cohorts

From: T-cell dysregulation is associated with disease severity in Parkinson’s Disease

  n Age Sex (f/m) Age at diagnosis Disease duration Progression rate Disease severity T-cells
% CD3 +  % CD4 +  % CD8 + 
Immunophenotyping (Figs. 1, 2) 36 Information available: n = 36/36 Information available: n = 36/36
Mean ± stdev 70.3 ± 9.5 12/24 60.0 ± 9.8 10.3 ± 6.0 0.33 ± 0.32 2.4 ± 0.94 11.5 ± 5.4 7.8 ± 3.4 2.4 ± 2.5
Median (interq. range) 72.1 (63.8–78.1) 62.5 (52.8–66.0) 8.7 (7.0–14.8) 0.25 (0.20–0.40) 2.0 (1.0–3.0) 9.8 (8.6–13.2) 6.7 (6.0–8.4) 1.8 (1.1–2.9)
Gene expession (Fig. 3) 16 Information available: n = 16/16 Information available: n = 10/16
Mean ± stdev 68.1 ± 9.6 4/12 58.7 ± 11.2 9.4 ± 7.5 0.44 ± 0.58 2.3 ± 0.99 14.7 ± 7.6 9.4 ± 4.5 3.9 ± 4.1
Median (interq. range) 70.5 (64.0–74.0) 59.0 (47.8–67.8) 7.0 (5.0–11.0) 0.22 (0.19–0.50) 2.0 (1.5–2.6) 10.9 (9.3–19.5) 6.7 (6.4–12.1) 2.8 (1.7–4.1)
T-cell function (Fig. 4) 23 Information available: n = 23/23 Information available: n = 0/23
Mean ± stdev 68.9 ± 10.5 6/17 60.2 ± 9.2 8.7 ± 6.2 0.51 ± 0.46 2.4 ± 1.0
Median (interq. range) 67.0 (63.5–78.5) 60.0 (51.5–69.0) 8.0 (3.0–13.5) 0.31 (0.24–0.83) 2.0 (2.0–3.0)
  n Medication Comorbidities
No medication Levodopa Dopamine Agonists COMT Inhibitors MAO-B Inhibitors DOPA-decarboxylase Inhibitors No comorbidities Dementia Hallucinations Other comorbidities
Immunophenotyping (Figs. 1, 2) 36 Information available: n = 32/36 Information available: n = 33/36
n 0/32 28/32 22/32 18/32 14/32 28/32 3/33 1/33 5/33 30/33
Gene expression (Fig. 3) 16 Information available: n = 13/16 Information available: n = 13/16
n 0/13 12/13 9/13 6/13 4/13 12/13 2/13 1/13 3/13 11/13
T-cell function (Fig. 4) 23 Information available: n = 23/23 Information available: n = 0/23
n 0/23 14/23 12/23 8/23 13/23 14/23
  1. Continuous variables presented as mean ± standard deviation (“stdev”) and median with interquartile range (“interq. range”, 1. and 3. quartile). Side effects from medication are not included in comorbidities. Comorbidities listed under “Others”: Anxiety disorder, atherosclerosis, bursitis, Carpal tunnel syndrome, cholelithiasis, chronic kidney failure, chronic venous insufficiency, reactive collagenosis, convex scoliosis, COPD, coronary bypass, coronary heart disease, Crohn’s disease, degenerative joint disease, degenerative spine disease, depression, diplopia, dorsal funiculus symptoms, heart arrythmia with atrial fibrillation, heart valve fibrosis, heart valve sclerosis, hemodynamic orthostatic vertigo, hypercholesterolemia, hyperlipoproteinemia, hyperopia, hyperparathyroidism, hypertension, hyperuricemia, hypothyroidism, inclusion body myositis, lactose intolerance, lentigo maligna, lumbago, mitral insufficiency, myalgia, myopathy, nephrolithiasis, osteochondrosis, osteoporosis, chronic pain syndrome, polyarthritis, prostatic adenoma, sensorymotor polyneuropathy, sleep apnea, spinal disc herniation, supraventricular extrasystole, tachycardia, thrombophlebitis, tinnitus, type 2 diabetes, vitamin B12 deficiency
  2. COMT catechol-O-methyltransferase, MAO-B Monoamine oxidase B, DOPA 3,4-dihydroxyphenylalanine